1
|
Bagardi M, Zamboni V, Locatelli C, Galizzi A, Ghilardi S, Brambilla PG. Management of Chronic Congestive Heart Failure Caused by Myxomatous Mitral Valve Disease in Dogs: A Narrative Review from 1970 to 2020. Animals (Basel) 2022; 12:ani12020209. [PMID: 35049831 PMCID: PMC8773235 DOI: 10.3390/ani12020209] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2021] [Revised: 01/12/2022] [Accepted: 01/13/2022] [Indexed: 12/12/2022] Open
Abstract
Simple Summary Myxomatous mitral valve disease (MMVD) is the most common acquired cardiovascular disease in dogs. The progression of the disease and the increasing severity of valvular regurgitation cause a volume overload of the left heart, leading to left atrial and ventricular remodeling and congestive heart failure (CHF). The treatment of chronic CHF secondary to MMVD in dogs has not always been the same over time. In the last fifty years, the drugs utilized have considerably changed, as well as the therapeutic protocols. Some drugs have also changed their intended use. An analysis of the literature concerning the therapy of chronic heart failure in dogs affected by this widespread degenerative disease is not available; a synthesis of the published literature on this topic and a description of its current state of art are needed. To the authors’ knowledge, a review of this topic has never been published in veterinary medicine; therefore, the aim of this study is to overview the treatments of chronic CHF secondary to MMVD in dogs from 1970 to 2020 using the general framework of narrative reviews. Abstract The treatment of chronic congestive heart failure (CHF), secondary to myxomatous mitral valve disease (MMVD) in dogs, has considerably changed in the last fifty years. An analysis of the literature concerning the therapy of chronic CHF in dogs affected by MMVD is not available, and it is needed. Narrative reviews (NRs) are aimed at identifying and summarizing what has been previously published, avoiding duplications, and seeking new study areas that have not yet been addressed. The most accessible open-access databases, PubMed, Embase, and Google Scholar, were chosen, and the searching time frame was set in five decades, from 1970 to 2020. The 384 selected studies were classified into categories depending on the aim of the study, the population target, the pathogenesis of MMVD (natural/induced), and the resulting CHF. Over the years, the types of studies have increased considerably in veterinary medicine. In particular, there have been 43 (24.29%) clinical trials, 41 (23.16%) randomized controlled trials, 10 (5.65%) cross-over trials, 40 (22.60%) reviews, 5 (2.82%) comparative studies, 17 (9.60%) case-control studies, 2 (1.13%) cohort studies, 2 (1.13%) experimental studies, 2 (1.13%) questionnaires, 6 (3.40%) case-reports, 7 (3.95%) retrospective studies, and 2 (1.13%) guidelines. The experimental studies on dogs with an induced form of the disease were less numerous (49–27.68%) than the studies on dogs affected by spontaneous MMVD (128–72.32%). The therapy of chronic CHF in dogs has considerably changed in the last fifty years: in the last century, some of the currently prescribed drugs did not exist yet, while others had different indications.
Collapse
|
2
|
Morningstar JE, Nieman A, Wang C, Beck T, Harvey A, Norris RA. Mitral Valve Prolapse and Its Motley Crew-Syndromic Prevalence, Pathophysiology, and Progression of a Common Heart Condition. J Am Heart Assoc 2021; 10:e020919. [PMID: 34155898 PMCID: PMC8403286 DOI: 10.1161/jaha.121.020919] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/20/2021] [Accepted: 04/21/2021] [Indexed: 01/01/2023]
Abstract
Mitral valve prolapse (MVP) is a commonly occurring heart condition defined by enlargement and superior displacement of the mitral valve leaflet(s) during systole. Although commonly seen as a standalone disorder, MVP has also been described in case reports and small studies of patients with various genetic syndromes. In this review, we analyzed the prevalence of MVP within syndromes where an association to MVP has previously been reported. We further discussed the shared biological pathways that cause MVP in these syndromes, as well as how MVP in turn causes a diverse array of cardiac and noncardiac complications. We found 105 studies that identified patients with mitral valve anomalies within 18 different genetic, developmental, and connective tissue diseases. We show that some disorders previously believed to have an increased prevalence of MVP, including osteogenesis imperfecta, fragile X syndrome, Down syndrome, and Pseudoxanthoma elasticum, have few to no studies that use up-to-date diagnostic criteria for the disease and therefore may be overestimating the prevalence of MVP within the syndrome. Additionally, we highlight that in contrast to early studies describing MVP as a benign entity, the clinical course experienced by patients can be heterogeneous and may cause significant cardiovascular morbidity and mortality. Currently only surgical correction of MVP is curative, but it is reserved for severe cases in which irreversible complications of MVP may already be established; therefore, a review of clinical guidelines to allow for earlier surgical intervention may be warranted to lower cardiovascular risk in patients with MVP.
Collapse
Affiliation(s)
- Jordan E. Morningstar
- Department of Regenerative Medicine and Cell BiologyMedical University of South CarolinaCharlestonSC
| | - Annah Nieman
- Department of Regenerative Medicine and Cell BiologyMedical University of South CarolinaCharlestonSC
| | - Christina Wang
- Department of Regenerative Medicine and Cell BiologyMedical University of South CarolinaCharlestonSC
| | - Tyler Beck
- Department of Regenerative Medicine and Cell BiologyMedical University of South CarolinaCharlestonSC
| | - Andrew Harvey
- Department of Regenerative Medicine and Cell BiologyMedical University of South CarolinaCharlestonSC
| | - Russell A. Norris
- Department of Regenerative Medicine and Cell BiologyMedical University of South CarolinaCharlestonSC
| |
Collapse
|
3
|
Vasava MS, Bhoi MN, Rathwa SK, Jethava DJ, Acharya PT, Patel DB, Patel HD. Benzimidazole: A Milestone in the Field of Medicinal Chemistry. Mini Rev Med Chem 2020; 20:532-565. [DOI: 10.2174/1389557519666191122125453] [Citation(s) in RCA: 37] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2018] [Revised: 05/05/2019] [Accepted: 09/06/2019] [Indexed: 02/07/2023]
Abstract
In the last 2-3 decades, the broad research in the application of benzimidazole derivatives
made it important for mankind. Many scientists have worked on benzimidazole derivatives and they
found that this compound has a diverse role in the field of medicinal chemistry. Few benzimidazole derivatives
are currently in the market as a drug candidate against various diseases. Moreover, the benzimidazole
derivatives exhibit pharmacological activities such as anti-tuberculosis, anti-malarial, antihistamine,
antimicrobial, antiviral, antidiabetic, anticancer, anti-fungal, anti-inflammatory, analgesic,
anti-HIV, etc. In this review, we have summarized various derivatives of benzimidazole which have
been prepared by many researchers to understand the chemistry as well as diverse pharmacological activities.
These findings may lead the scientists who are working in the field of medicinal chemistry to
the development of benzimidazole based drug candidates in the future.
Collapse
Affiliation(s)
- Mahesh S. Vasava
- Department of Chemistry, School of Sciences, Gujarat University, Ahmedabad, Gujarat, India
| | - Manoj N. Bhoi
- Piramal Enterprise Ltd, Plot No.-18, Pharmez, Matoda Village, Ahmedabad, India
| | - Sanjay K. Rathwa
- Department of Chemistry, School of Sciences, Gujarat University, Ahmedabad, Gujarat, India
| | - Divya J. Jethava
- Department of Chemistry, School of Sciences, Gujarat University, Ahmedabad, Gujarat, India
| | - Prachi T. Acharya
- Department of Chemistry, School of Sciences, Gujarat University, Ahmedabad, Gujarat, India
| | - Dhaval B. Patel
- Department of Chemistry, School of Sciences, Gujarat University, Ahmedabad, Gujarat, India
| | - Hitesh D. Patel
- Department of Chemistry, School of Sciences, Gujarat University, Ahmedabad, Gujarat, India
| |
Collapse
|
4
|
Nikoofar K, Dizgarani SM. HNO 3 @nano SiO 2 : An efficient catalytic system for the synthesis of multi-substituted imidazoles under solvent-free conditions. JOURNAL OF SAUDI CHEMICAL SOCIETY 2017. [DOI: 10.1016/j.jscs.2015.11.006] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
5
|
|
6
|
Development of drugs based on imidazole and benzimidazole bioactive heterocycles: recent advances and future directions. Med Chem Res 2015. [DOI: 10.1007/s00044-015-1495-5] [Citation(s) in RCA: 171] [Impact Index Per Article: 19.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
|
7
|
Reina-Doreste Y, Stern JA, Keene BW, Tou SP, Atkins CE, DeFrancesco TC, Ames MK, Hodge TE, Meurs KM. Case-control study of the effects of pimobendan on survival time in cats with hypertrophic cardiomyopathy and congestive heart failure. J Am Vet Med Assoc 2015; 245:534-9. [PMID: 25148095 DOI: 10.2460/javma.245.5.534] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
OBJECTIVE To assess survival time and adverse events related to the administration of pimobendan to cats with congestive heart failure (CHF) secondary to hypertrophic cardiomyopathy (HCM) or hypertrophic obstructive cardiomyopathy (HOCM). DESIGN Retrospective case-control study. ANIMALS 27 cats receiving treatment with pimobendan and 27 cats receiving treatment without pimobendan. PROCEDURES Medical records between 2003 and 2013 were reviewed. All cats with HCM or HOCM treated with a regimen that included pimobendan (case cats) were identified. Control cats (cats with CHF treated during the same period with a regimen that did not include pimobendan) were selected by matching to case cats on the basis of age, sex, body weight, type of cardiomyopathy, and manifestation of CHF. Data collected included signalment, physical examination findings, echocardiographic data, serum biochemical values, and survival time from initial diagnosis of CHF. Kaplan-Meier survival curves were constructed and compared by means of a log rank test. RESULTS Cats receiving pimobendan had a significant benefit in survival time. Median survival time of case cats receiving pimobendan was 626 days, whereas median survival time for control cats not receiving pimobendan was 103 days. No significant differences were detected for any other variable. CONCLUSIONS AND CLINICAL RELEVANCE The addition of pimobendan to traditional treatment for CHF may provide a substantial clinical benefit in survival time for HCM-affected cats with CHF and possibly HOCM-affected cats with CHF.
Collapse
Affiliation(s)
- Yamir Reina-Doreste
- Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27607
| | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Rodrigues T, Lin YC, Hartenfeller M, Renner S, Lim YF, Schneider G. Repurposing de novo designed entities reveals phosphodiesterase 3B and cathepsin L modulators. Chem Commun (Camb) 2015; 51:7478-81. [DOI: 10.1039/c5cc01376c] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Scaffold hopping: a computational algorithm correctly predicted the macromolecular target ofde novogenerated small molecular entities.
Collapse
Affiliation(s)
- Tiago Rodrigues
- Swiss Federal Institute of Technology (ETH)
- Department of Chemistry and Applied Biosciences
- 8093 Zürich
- Switzerland
| | - Yen-Chu Lin
- Swiss Federal Institute of Technology (ETH)
- Department of Chemistry and Applied Biosciences
- 8093 Zürich
- Switzerland
| | - Markus Hartenfeller
- Swiss Federal Institute of Technology (ETH)
- Department of Chemistry and Applied Biosciences
- 8093 Zürich
- Switzerland
- Novartis Pharma AG
| | | | - Yi Fan Lim
- Swiss Federal Institute of Technology (ETH)
- Department of Chemistry and Applied Biosciences
- 8093 Zürich
- Switzerland
| | - Gisbert Schneider
- Swiss Federal Institute of Technology (ETH)
- Department of Chemistry and Applied Biosciences
- 8093 Zürich
- Switzerland
| |
Collapse
|
9
|
Svennebring AM. Investigation of the prerequisites for the optimization of specific plasma protein binding as a strategy for the reduction of first-pass hepatic metabolism. Xenobiotica 2014; 45:286-301. [PMID: 25364858 DOI: 10.3109/00498254.2014.978413] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
1. It is hypothesized that the deliberate structural tailoring of compounds designed for drug use to increase the specific plasma protein binding can be used to reduce first-pass hepatic metabolism. To test the feasibility of this hypothesis, a dataset of drugs with plasma protein binding of 90% or above divided into three classes including 50 acids, 44 bases and 69 neutrals was analyzed. 2. Among the drugs with ≥99% plasma protein binding, the fraction of the total dose existing in free form in vivo (free dose fraction) decreased in the following order: acids (0.55%) > neutrals (0.16%) > bases (0.08%). The order was different for the fraction of the total dose that existed in plasma protein bound form (plasma protein bound dose fraction): acids (58%) > neutrals (17%) = bases (18%). 3. The free fraction was poorly correlated with the partition coefficient (Log P). The lower aqueous solubility associated with high plasma protein binding was explained by differences in Log P and not by the plasma protein binding per se. The logarithm of the extrarenal clearance was correlated with Log P. For acids and bases, extrarenal clearance was also correlated with fu. For neutrals, plasma protein binding had no protective effect.
Collapse
Affiliation(s)
- Andreas Mats Svennebring
- Department of Pharmaceutical Biosciences, Uppsala Biomedical Center, Uppsala University , Uppsala , Sweden
| |
Collapse
|
10
|
Zvirgzdins A, Delina M, Mishnev A, Actins A. Pimobendan B from powder diffraction data. Acta Crystallogr Sect E Struct Rep Online 2013; 69:o1677. [PMID: 24526935 PMCID: PMC3919548 DOI: 10.1107/s1600536813028353] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2013] [Accepted: 10/15/2013] [Indexed: 05/28/2023]
Abstract
The title mol-ecule, C19H18N4O2 {systematic name: (RS)-6-[2-(4-meth-oxy-phen-yl)-1H-benzimidazol-5-yl]-5-methyl-4,5-di-hydro-pyridazin-3(2H)-one}, adopts an extended conformation. The dihedral angles between the central benzimidazole ring sytem and the pendant meth-oxy-phenyl and pyridazinone residues are 1.41 (18) and 9.7 (3)°, respectively. In the crystal, N-H⋯N hydrogen bonds link the imadazole groups into [001] chains, and pairs of N-H⋯O hydrogen bonds link the pyridazinone groups into dimers. Together, these generate a two-dimensional supra-molecular structure parallel to (010). The layers are linked by C-H⋯π inter-actions.
Collapse
Affiliation(s)
- Alvis Zvirgzdins
- University of Latvia, Department of Chemistry, Kr. Valdemara Street 48, Riga, LV-1013, Latvia
| | - Mara Delina
- University of Latvia, Department of Chemistry, Kr. Valdemara Street 48, Riga, LV-1013, Latvia
| | - Anatoly Mishnev
- Latvian Institute of Organic Synthesis, Aizkraukles Street 21, Riga, LV-1006, Latvia
| | - Andris Actins
- University of Latvia, Department of Chemistry, Kr. Valdemara Street 48, Riga, LV-1013, Latvia
| |
Collapse
|
11
|
Reinker LN, Lee JA, Hovda LR, Rishniw M. Clinical Signs of Cardiovascular Effects Secondary to Suspected Pimobendan Toxicosis in Five Dogs. J Am Anim Hosp Assoc 2012; 48:250-5. [DOI: 10.5326/jaaha-ms-5775] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
The purpose of this study was to review the medical records of dogs that were either suspected or known to have ingested large doses of pimobendan and to describe the clinical signs associated with pimobendan toxicosis. The database of Pet Poison Helpline, an animal poison control center located in Minneapolis, MN, was searched for cases involving pimobendan toxicosis from Nov 2004 to Apr 2010. In total, 98 cases were identified. Of those, seven dogs that ingested between 2.6 mg/kg and 21.3 mg/kg were selected for further evaluation. Clinical signs consisted of cardiovascular abnormalities, including severe tachycardia (4/7), hypotension (2/7), and hypertension (2/7). In two dogs, no clinical signs were seen. Despite a wide safety profile, large overdoses of pimobendan may present risks for individual pets. Prompt decontamination, including emesis induction and the administration of activated charcoal, is advised in the asymptomatic patient. Symptomatic and supportive care should include the use of IV fluid therapy to treat hypotension and address hydration requirements and blood pressure and electrocardiogram monitoring with high-dose toxicosis. Practitioners should be aware of the clinical signs associated with high-dose pimobendan toxicosis. Of the dogs reported herein, all were hospitalized, responded to supportive care, and survived to discharge within 24 hr of exposure.
Collapse
Affiliation(s)
- L. Noelani Reinker
- Metropolitan Veterinary Referral Services, Eden Prairie, MN (L.R.); Pet Poison Helpline, Minneapolis, MN (J.L., L.H); and Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY (M.R.)
| | - Justine A. Lee
- Metropolitan Veterinary Referral Services, Eden Prairie, MN (L.R.); Pet Poison Helpline, Minneapolis, MN (J.L., L.H); and Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY (M.R.)
| | - Lynn R. Hovda
- Metropolitan Veterinary Referral Services, Eden Prairie, MN (L.R.); Pet Poison Helpline, Minneapolis, MN (J.L., L.H); and Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY (M.R.)
| | - Mark Rishniw
- Metropolitan Veterinary Referral Services, Eden Prairie, MN (L.R.); Pet Poison Helpline, Minneapolis, MN (J.L., L.H); and Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY (M.R.)
| |
Collapse
|
12
|
|
13
|
Nandi S, Samanta S, Jana S, Ray JK. Synthesis of substituted benzimidazo[2,1-a]isoquinolines and its condensed analogues using Pd(0)-catalyzed cyclization/C–H activation. Tetrahedron Lett 2010. [DOI: 10.1016/j.tetlet.2010.07.162] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
14
|
Caro A, Ynaraja E, Montoya JA. Effects of Short-term Treatment with Pimobendan in Dogs with Myxomatous Valve Disease. JOURNAL OF APPLIED ANIMAL RESEARCH 2009. [DOI: 10.1080/09712119.2009.9706999] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
|
15
|
Rao YJ, Xi L. Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts. Acta Pharmacol Sin 2009; 30:1-24. [PMID: 19060915 DOI: 10.1038/aps.2008.1] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Abstract
Phosphodiesterases (PDEs) are enzymes that degrade cellular cAMP and cGMP and are thus essential for regulating the cyclic nucleotides. At least 11 families of PDEs have been identified, each with a distinctive structure, activity, expression, and tissue distribution. The PDE type-3, -4, and -5 (PDE3, PDE4, PDE5) are localized to specific regions of the cardiomyocyte, such as the sarcoplasmic reticulum and Z-disc, where they are likely to influence cAMP/cGMP signaling to the end effectors of contractility. Several PDE inhibitors exhibit remarkable hemodynamic and inotropic properties that may be valuable to clinical practice. In particular, PDE3 inhibitors have potent cardiotonic effects that can be used for short-term inotropic support, especially in situations where adrenergic stimulation is insufficient. Most relevant to this review, PDE inhibitors have also been found to have cytoprotective effects in the heart. For example, PDE3 inhibitors have been shown to be cardioprotective when given before ischemic attack, whereas PDE5 inhibitors, which include three widely used erectile dysfunction drugs (sildenafil, vardenafil and tadalafil), can induce remarkable cardioprotection when administered either prior to ischemia or upon reperfusion. This article provides an overview of the current laboratory and clinical evidence, as well as the cellular mechanisms by which the inhibitors of PDE3, PDE4 and PDE5 exert their beneficial effects on normal and ischemic hearts. It seems that PDE inhibitors hold great promise as clinically applicable agents that can improve cardiac performance and cell survival under critical situations, such as ischemic heart attack, cardiopulmonary bypass surgery, and heart failure.
Collapse
|